333456-14-7Relevant articles and documents
Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: Orally active inhibitors of lck kinase
Goldberg, Daniel R.,Butz, Tanja,Cardozo, Mario G.,Eckner, Robert J.,Hammach, Abdelhakim,Huang, Jessica,Jakes, Scott,Kapadia, Suresh,Kashem, Mohammed,Lukas, Susan,Morwick, Tina M.,Panzenbeck, Maret,Patel, Usha,Pav, Susan,Peet, Gregory W.,Peterson, Jeffrey D.,Prokopowicz III, Anthony S.,Snow, Roger J.,Sellati, Rosemarie,Takahashi, Hidenori,Tan, Jonathan,Tschantz, Matt A.,Wang, Xiao-Jun,Wang, Yong,Wolak, John,Xiong, Pla,Moss, Neil
, p. 1337 - 1349 (2007/10/03)
The tyrosine kinase p56lck (lck) is essential for T cell activation; thus, inhibitors of lck have potential utility as autoimmune agents. Our initial disclosure of a new class of lck inhibitors based on the phenylaminoimidazoisoquinolin-9-one showed reaso
Heterocyclic compounds useful as inhibitors of tyrosine kinases
-
, (2008/06/13)
Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases asso